Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Thursday 08 September, 2011

Xenetic Biosciences

US Patent update

RNS Number : 8398N
Xenetic Biosciences PLC
08 September 2011



Xenetic Biosciences plc

 ('Xenetic Biosciences' or the 'Company')


US Patent update


Xenetic Biosciences plc (AIM: XEN.L), the bio-pharmaceutical company specialising in the development of high-value differentiated biologic drugs and vaccines, announces that it has received a notice of allowance of a patent application that covers the Company's co-delivery technology in the US. The application will proceed to grant shortly and Xenetic Biosciences will provide an update once the patent has been granted.


Xenetic Biosciences' co-delivery patent deals with a unique method of genetic immunisation. The method consists of packaging a protein vaccine together with a plasmid DNA that encodes the vaccine, in the same liposome and regardless of the liposome size. This ensures that both, the protein vaccine and the DNA encoding the vaccine are delivered simultaneously (co-delivery) in the same antigen presenting cells.


The patent provides protection for Xenetic Biosciences' co-delivery technology that is used in the Company's ImuXen product range. Xenetic Biosciences' ImuXen liposomal technology platform can be used to create and deliver DNA, protein based vaccines capable of generating enhanced immune responses.


Xenetic Biosciences already has Patents granted in relation to this technology in Europe, Russia and China as well as separate Patents that cover their polysaccharide based vaccines.






Xenetic Biosciences plc 

M. Scott Maguire, Chief Executive Officer

+44 (0)20 7389 5015

Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång

Walbrook PR

+44 (0)20 7933 8780

Paul McManus

Paul Cornelius



This information is provided by RNS
The company news service from the London Stock Exchange